Issue 24, Volume 128

Cover Figure:  Type I interferon–induced thrombotic microangiopathy.  See the article by Kavanagh et al.

WASHINGTON, December 15, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Minimal residual disease is an independent predictor for 10-year survival in CLL
Kwok and colleagues report a retrospective study of the impact of minimal residual disease (MRD) negativity on clinical outcomes in chronic lymphocytic leukemia (CLL), reporting that patients who are MRD negative have an impressive increase in 10-year progression-free and overall survival over MRD-positive patients.

Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice
Zhang et al report that metformin improves hematopoiesis and delays tumor formation in a Fancd2-null mouse model of Fanconi anemia (FA). They suggest that metformin may reduce DNA damage to FA cells through detoxification of aldehyde species.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
Chiron and colleagues report a novel ex vivo culture system for mantle cell lymphoma (MCL) cells cocultured with lymphoid-like cells. They demonstrate that the interaction with CD40L+ cells alters mitochondrial priming for apoptosis, leading to drug resistance that can be reversed with obinutuzumab.

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
Kavanagh et al present an elegant bench-to-bedside demonstration that type I interferon causes a dose-dependent thrombotic microangiopathy. They propose a clinical strategy that can prevent this potentially life-threatening complication.

Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity
Best known for its role in the contact pathway of coagulation, factor XII is also known to contribute to fibrinolysis. Mitchell and colleagues report that platelet polyphosphate complexes with factor XIIa on platelet membranes and promotes fibrinolysis by facilitating plasminogen activator activity.

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
In a timely Perspective article, Rajkumar and Harousseau discuss the financial challenges of current treatment of multiple myeloma in the context of increasing numbers of novel therapies and longer patient survival.

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients
In a brief report, Stringaris et al report that activating killer immunoglobulin-like receptors (aKIRs) influence outcome in myelodysplastic syndromes (MDS). MDS and secondary acute myeloid leukemia are associated with a smaller median number of aKIR genes, underscoring the role of immunosurveillance in MDS outcomes.


This week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.